Zymeworks falls after halting cancer drug development

Zymeworks

02/09/2025 13:34

** Shares of drug developer Zymeworks ZYME.O fall 14.7% to $12.63 premarket

** Co to stop developing its experimental cancer drug, ZW171, after results from a trial showed the treatment was unlikely to benefit as a standalone therapy

** The Vancouver-based company was testing the drug in an early-stage trial for patients with ovarian and non-small cell lung cancers

** As of last close, ZYME stock up 1.16% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))